Introduction
============

Nitrogen dioxide (NO~2~), a ubiquitous atmospheric pollutant, is a respiratory irritant that remains a matter of concern \[[@r44]\]. Indoor concentrations of NO~2~ often exceed those found outdoors, especially when unvented combustion appliances are used. Inside homes, peak levels of NO~2~, associated with the use of gas and solid-fuel appliances for cooking and heating, have been measured in the range of 80--1,100 ppb (150--2,090 μg/m^3^) ([@r5]; [@r9]; [@r26]; [@r31]). Outdoors, hourly NO~2~ concentrations in cities rarely exceed 200 ppb (380 μg/m^3^) ([@r41]), although urban levels can reach levels as high as 500 ppb (950 μg/m^3^) ([@r43]), especially for short periods in streets with heavy traffic and in road tunnels ([@r27]).

Epidemiological and controlled human exposure studies suggest that people with asthma are more susceptible to the effects of NO~2~ when compared with healthy individuals ([@r6]; [@r7]; [@r8]; [@r15]; [@r22]; [@r38]).

However, despite the extensive literature on NO~2~-induced health effects, some inconsistencies in the results of studies have been noted ([@r20]). In asthmatics, NO~2~ exposure without allergen challenge did not result in lung functional changes in most studies ([@r2]; [@r25]; [@r28]; [@r29]), and inconsistent results were found in airway responsiveness after nonspecific bronchoconstrictor challenges ([@r8]; [@r16]; [@r23]; [@r25]; [@r35]; [@r38]). After allergen challenge, exposure to NO~2~ in asthmatics increased airway hyperresponsiveness ([@r21]; [@r37], [@r39]; [@r40]) and eosinophilic inflammation ([@r4], [@r3]).

A few studies have investigated the inflammatory response to a single exposure of NO~2~ without allergen challenge in asthmatics, but the findings have been inconsistent ([@r24]; [@r36]; [@r42]).

We investigated whether repeated brief exposures to 200 ppb (380 μg/m^3^) and 600 ppb (1,130 μg/m^3^) NO~2~, which mimic indoor NO~2~ peaks, enhance airway inflammation in asthmatics. This clinical study involved 19 adults with intermittent asthma and used a randomized double-blind protocol with assessment of inflammatory response in induced sputum.

Materials and Methods
=====================

*Participants*. Nineteen patients \[14 men and 5 women; median age, 29 years; age range, 20--69 years; median body mass index (BMI), 26 kg/m^2^; BMI range, 20--39 kg/m^2^\] were included in the study ([Table 1](#t1){ref-type="table"}). All had intermittent asthma as defined by the [@r12] guidelines and were nonsmokers (18 had never smoked and 1 had stopped smoking some 10 years earlier). Only patients who had a diagnosis of asthma confirmed by a positive methacholine challenge performed twice at baseline 10--30 days before the first exposure were included in the study. A positive methacholine test was defined as a methacholine provocative dose causing a 20% decrease in forced expiratory volume in 1 sec (FEV~1~) from control FEV~1~ (PD~20~ methacholine) \< 4 mg. All participants had allergy to house dust mites (HDM) and/or pollen confirmed by a positive skin-prick test done ≥ 4 weeks before their inclusion in the study. The study was performed outside the pollen season for those who had been diagnosed with pollen allergies. Of the 19 participants, 6 had a personal history of atopic dermatitis and/or an atopic familial history. None of those six used inhaled or oral corticosteroids or other antiinflammatory therapy, and the only permitted medication was an inhaled β~2~-agonist, used as needed during the study period (from baseline, i.e., 30 days before the first NO~2~ exposure until the end of the study 2 weeks after the last exposure). Participants who had gas stoves and/or unvented combustion appliances at home were told not to use them at baseline and on the days of exposures and during the 2 days before and after NO~2~ exposure. All participants had to be free of airway infection for at least 6 weeks before baseline measurements.

###### 

Characteristics of participants.

  Participant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Age (years)   History of atopy^*a*^   Smoking status   Sex   Height (cm)   Weight (kg)   BMI (kg/m^2^)   Asthma duration (years)   FEV~1~ at inclusion (FEV~1~ % predicted)   PD20 methacholine at baseline (μg)   Percent eosinophils in sputum at baseline^*b*^
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ----------------------- ---------------- ----- ------------- ------------- --------------- ------------------------- ------------------------------------------ ------------------------------------ ------------------------------------------------
  1^*c*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       26            Yes                     N                F     164           57            21              8                         3.23 (110)                                 1,600                                NA
  2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            29            No                      E                M     185           90            27              11                        4.13 (89)                                  1,490                                14.73
  3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            29            No                      N                M     182           87            27              10                        4.43 (99)                                  690                                  11.88
  4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            31            No                      N                M     161           84            33              8                         2.87 (81)                                  3,200                                6.79
  5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            28            No                      N                M     174           74            25              4                         3.69 (88)                                  1,550                                1.68
  6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            27            No                      N                M     180           88            28              21                        3.57 (80)                                  1,220                                0.93
  7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            24            No                      N                M     178           70            22              8                         3.88 (87)                                  1,070                                4.25
  8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            30            No                      N                F     159           56            22              20                        3.03 (103)                                 500                                  2.68
  9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            29            Yes                     N                M     168           72            26              22                        3.89 (100)                                 3,200                                1.88
  10^*c*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      28            Yes                     N                M     186           92            27              2                         4.49 (96)                                  800                                  ANR
  11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           20            Yes                     N                F     158           49            20              9                         2.29 (76)                                  930                                  0.26
  12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           69            No                      N                M     178           90            29              5                         2.49 (78)                                  3,200                                17.72
  13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           30            No                      N                F     163           55            21              20                        2.68 (87)                                  1,950                                32.08
  14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           32            Yes                     N                M     179           82            26              24                        4.12 (92)                                  340                                  2.51
  15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           24            No                      N                F     171           60            21              14                        3.41 (97)                                  310                                  5.12
  16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           28            No                      N                M     174           62            21              16                        3.82 (91)                                  2,100                                20.58
  17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           32            No                      N                M     176           115           38              21                        4.16 (100)                                 2,170                                2.99
  18^*c*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      30            Yes                     N                M     169           89            32              21                        3.75 (95)                                  190                                  NA
  19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           30            No                      N                M     174           115           39              23                        3.16 (76)                                  210                                  1.55
  Abbreviations: ANR: available but not relevant because participant 10 did not complete the three series of exposure; E, ex-smoker; N, never-smoker; NA: not available. ^***a***^Personal history of atopic dermatitis and/or atopic familial history. ^***b***^Percent eosinophils at baseline (10--30 days before first exposure). ^***c***^Participants excluded from the analysis: participants 1 and 18 did not produce adequate sputum specimens for cell analysis at baseline (squamous cells \> 20%); participant 10 did not complete the three series of exposure.                                                                                                                                                                                                                      

The study was registered by the French Ministry of Health (DGS 2006/0016) and approved by the Ethics Committee of Hotel-Dieu Hospital, Paris, France (project 0611398, registered on 28 February 2007). All participants signed informed consent forms before enrollment in the study.

*Study design*. The study had a double-blind, crossover design, with each participant acting as his or her own control. For each participant, the study involved three series each of three exposures at rest: one series to clean air, one series to 200 ppb (380 μg/m^3^) NO~2~, and one series to 600 ppb (1,130 μg/m^3^) NO~2~. The order of the three series of exposures was randomized ([Figure 1](#f1){ref-type="fig"}). The design for each series of exposures with the timing of pulmonary function testing, and sputum inductions from day 1 to day 3 is described in [Figure 2](#f2){ref-type="fig"}. For each series, participants were exposed to the same level of NO~2~ or to clean air once for 30 min on day 1, and twice for 30 min on day 2, at the same time and on the same days of the week. The two exposures performed on day 2 were separated by 1 hr. There was no exposure on day 3. There was an interval of 2 weeks between each series of exposures. Only the engineer in charge of injection into the chamber knew whether the participant was being exposed to NO~2~ or clean air.

![Flow diagram of the study period for each participant. Abbreviations: H0, immediately before 1st exposure (day 1); H0', immediately after 1st exposure (day 1); H6, 6 hr after H0' (day 1); H32, 32 hr after H0' (day 2); H48, 48 hr after H0' (day 3). The dose order was attributed randomly; so, series A, B, and C ­corresponds to clean air, 200-ppb NO~2~, or 600-ppb NO~2~ exposure.](ehp.1307240.g001){#f1}

![Study design for each of the three series of exposures separated by 2 weeks. Abbreviations: H0, immediately before 1st exposure (day 1); H0', immediately after 1st exposure (day 1); H6, 6 hr after H0' (day 1); H32, 32 hr after H0' (day 2); H48, 48 hr after H0' (day 3). Participants were exposed at rest in a double-blinded, randomized, crossover design to clean air, 200-ppb NO~2~, or 600 ppb NO~2~ once for 30 min on day 1, and twice for 30 min on day 2. There was no exposure on day 3. Time of day is expressed in military form.](ehp.1307240.g002){#f2}

Sputum was induced twice at baseline (10--30 days before first exposure, with 1--3 weeks between the sputum inductions) and for each series of exposures, 6 hr (on day 1), 32 hr (on day 2), and 48 hr (on day 3) after the end of the first exposure. Spirometry with flow--volume curves was carried out at baseline (immediately before first exposure) and daily from day 1 to day 3, before and immediately after exposures, and immediately before sputum inductions. Allergen challenge was not performed, either before or after the exposures.

*Nitrogen dioxide/clean air exposure*. The exposures were performed in an 8.8-m^3^ exposure chamber installed in the investigation clinical center at the Hospital Bichat in Paris as previously described ([@r10]). The chamber was supplied with fresh, particle-free air at a mean temperature of 25°C and a mean relative humidity of 32%. The air supply passed through HEPA and activated carbon filters. We used NO~2~ concentrated at 950 ppm compressed in a 20-L gas bottle under 150 bar pressure for the 600-ppb exposures, and a gas bottle of NO~2~ concentrated at 520 ppm under 150 bar pressure for the 200-ppb exposures (Air Liquide SA, Paris, France). A mass flow meter secured the stability of the injected flow at the expected concentration (200 ppb or 600 ppb).

During exposures, NO~2~ concentration inside the exposure chamber was continuously monitored (chemiluminescence oxides of nitrogen analyzer, Model AC 32 M; Environnement SA, 78300 Poissy, France). The mean concentration was 581 ppb ± 3.2% for 600-ppb NO~2~ exposures and 203 ppb ± 1.5% for 200-ppb NO~2~ exposures. During exposures to clean air, the NO~2~ concentration was \< 10 ppb.

*Pulmonary function and methacholine challenge testing*. Flow-volume curves were obtained using a Biomedin spirometer (Biomedin srl, Padova, Italy) according to the European Community Respiratory Health Survey specifications to determine FEV~1~ and peak expiratory flow (PEF) ([@r34]).

Methacholine challenge tests were done twice at baseline with an automatic inhalation-synchronized Mefar MB3 dosimeter jet nebulizer (Mefar spa, Bovezzo, Italy), as described elsewhere ([@r1]; [@r10]). Methacholine challenge tests at baseline were conducted 10--30 days before the start of the exposures to avoid any putative interference of the methacholine challenge with the effect of NO~2~ ([@r24]).

*Sputum induction and inflammatory marker measurements.* We performed sputum induction with an aerosol of hypertonic saline using the method of [@r32]. The sputum was analyzed within 1 hr according to [@r33], as described elsewhere ([@r10]). Total nonsquamous inflammatory cell counts were expressed as 10^3^ cells/mg of induced sputum. Differential cell counts were performed by counting 400 cells on May Grünwald Giemsa stained slides by two expert observers blinded to the participant's exposure. Results were expressed both as percentage and as number of inflammatory cells per milligram of induced sputum. Only samples with cell viability \> 70% and squamous cell contamination \< 20% were considered adequate.

Sputum supernatant concentrations of eosinophil cationic protein (ECP) levels were measured by a commercially available enzyme assay (CAP-FEIA; Pharmacia, St Quentin-en-Yvelines, France), with a lower detection limit of 2 ng/mL.

*Follow-up during the study period*. After 0, 15, and 30 min of exposure to NO~2~ or clean air in the chamber, participants were asked questions relating to respiratory symptoms and perception of discomfort.

FEV~1~ and PEF were monitored twice during exposure at 15-min intervals and hourly for 6 hr after leaving the chamber, with a portable combined spirometer (One Flow Tester; Mediflux, Croissy Beaubourg, France).

During the 10--30 days between baseline measurements and first exposure and during the 2-week interval following each series of exposures, subjective symptoms and medications were recorded every day. Each participant measured FEV~1~ and PEF twice daily with a portable combined spirometer.

*Sample size*. The primary end point was the change in the percentage of eosinophils in sputum, expressed as the ratio between the percentage after exposure and the baseline percentage. When the study was designed, literature reports were insufficient to determine the variance of the ratio, which was mandatory to estimate the sample size. Variance was estimated after inclusion of the first eight participants without unblinding. Based on the variance found of 0.10, a sample size of 18 participants was considered sufficient to demonstrate a doubling of the percentage of eosinophils in sputum with a power of 80% and a significance level of 0.05 (see Supplemental Material, Table S1). In addition, a doubling has been reported to be consistent with clinically relevant changes in clinical status of asthmatics ([@r13]).

*Statistical analysis*. The parameters studied in sputum were the percentage of eosinophils, the number of eosinophils per milligram, ECP, the number of neutrophils per milligram, and the number of macrophages per milligram. All parameters were log-transformed to normalize the distributions. We used a generalized linear model (GLM procedure, SAS v9.4; SAS Institute Inc., Cary, NC, USA) for the analyses. We included in the statistical model the effect of the participant, the time, the dose, and the interaction between the time and the dose. The interpretation of the results was based on the type III sum of squares. In case of a significant interaction between day and dose, a global analysis was performed, followed by per-day analyses. In the global analysis, all the data concerning the parameter were summarized by their geometric means (GMs) (in case of sputum inductions, this relates to three sputum inductions over 3 days, one per day), and we tested the relation between NO~2~ concentration---used as a quantitative value (0, 200, and 600 ppb)---and the parameter studied. The global analysis provided the *p*~trend~. To display the results in a meaningful way, we also analyzed the data using classes of exposure (without any preconceived idea on the form of the relationship): For each class of exposure, we estimated the least-square mean (LSMEAN) and its 95% confidence limits. The LSMEANs and the confidence limits were exponentiated to obtain the changes relative to the baseline measurements and their confidence intervals (CIs). The per-day analyses were reported only when the trend in the global analysis was significant. *p*-Values \< 0.05 were considered significant.

Results
=======

Among the 19 participants, 18 completed the three series of exposures and were included in the analysis. Among those, two did not produce an adequate sample of sputum at all time points and were not included in analyses of sputum ([Table 1](#t1){ref-type="table"}).

Respiratory function---FEV~1~ and PEF---measured by spirometry, did not significantly change after NO~2~ exposure compared with clean air exposure ([Table 2](#t2){ref-type="table"}). No major clinical adverse reactions, such as coughing, wheezing, or chest tightness suggesting asthma attacks, were observed during exposures or follow-up. During the 2 weeks after each exposure, subjective symptoms and peak flow measurements were not significantly different regardless of exposure.

###### 

GMs (95% CIs) of values relative to baseline of FEV1 and PEF evaluated in the 18 participants who completed the study.

  Variable                                                                                                                                                                                                                                                                                                                                                                                                                                                                0 ppb NO~2~ (clean air)   200 ppb NO~2~       600 ppb NO~2~       *p*-Value
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ------------------- ------------------- -----------
  FEV~1~/baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                         1.02 (1.00, 1.05)         1.00 (0.97, 1.03)   1.00 (0.98, 1.03)   0.41
  PEF/baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                            1.05 (0.99, 1.11)         1.04 (0.98, 1.10)   1.01 (0.96, 1.07)   0.36
  Baseline values were measured immediately before first exposure (H0 on day 1) for each series of exposure. Each value corresponds to the GM change from baseline of the six values \[H0', immediately after first exposure (day 1); H6, 6 hr after H0' (day 1); H32, 32 hr after H0' (day 2); H48, 48 hr after H0' (day 3)\] obtained by spirometry with flow-volume curves. The effects of exposure, regardless of the dose, on FEV~1~ and PEF were not significant.                                                                     

The primary analysis tested the exposure level (dose), the time (because the study design included assessment at three time points after exposure, one each day) and the interaction between time and exposure level. The dose was significantly related to the change in the percentage of eosinophils, the time was not. There was a significant interaction between time and exposure level, meaning that the association between dose and effect on eosinophils was different according to the day. As planned in the case of a significant interaction, we performed both a global analysis, averaging the measurements over the 3 days, and per-day analyses.

In the global analysis, the slope of the association between the percentage of eosinophils and NO~2~ exposure level was significant (*p* = 0.04) ([Table 3](#t3){ref-type="table"}).

###### 

Changes relative to baseline measurements (performed 10--30 days before the first exposure) for parameters measured in sputum \[GM % (95% CI), *n* = 16\].

  Variable                                                                                                                                                                             0 ppb NO~2~ (clean air)   200 ppb NO~2~     600 ppb NO~2~       *p*~Trend~
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------- ----------------- ------------------- ------------
  Percentage of eosinophils                                                                                                                                                            --12 (--34, 16)           --5 (--28, 26)    57 (18, 109)\*\*    0.04
  Day 1                                                                                                                                                                                16 (--28, 86)             --34 (--59, 6)    12 (--31, 79)       0.81
  Day 2                                                                                                                                                                                --5 (--37, 44)            --3 (--36, 46)    102 (32, 211)\*\*   0.01
  Day 3                                                                                                                                                                                --39 (--67, 13)           36 (--26, 149)    79 (--3, 230)       0.03
  No. of eosinophils/mg                                                                                                                                                                --5 (--31, 29)            23 (--10, 68)     120 (60, 202)^\#^   0.02
  Day 1                                                                                                                                                                                --5 (--44, 60)            --24 (--55, 29)   64 (--3, 177)       0.10
  Day 2                                                                                                                                                                                9 (--39, 95)              23 (--31, 119)    142 (32, 344)\*\*   0.06
  Day 3                                                                                                                                                                                --18 (--57, 56)           99 (5, 278)\*     163 (38, 398)\*\*   0.03
  ECP                                                                                                                                                                                  21 (--1, 47)              0 (--18, 22)      43 (17, 75)\*\*     0.23
  No. of neutrophils/mg                                                                                                                                                                12 (--17, 51)             --9 (--32, 22)    10 (--19, 49)       0.97
  No. of macrophages/mg                                                                                                                                                                --18 (--33, 0)            --2 (--20, 21)    --6 (--24, 15)      0.46
  GM percentages represent all changes of the parameter for the 3 days (one sputum induction per day). \**p* \< 0.05; \*\**p* \< 0.01; and ^\#^*p* \< 0.001, compared with baseline.                                                                   

Compared with baseline measurements, the percentage of eosinophils in sputum increased by 57% (95% CI: 18, 109%) after 600 ppb NO~2~ (*p* = 0.003) but did not change significantly after clean air or after 200 ppb NO~2~.

Similar results were found for the association between the number of eosinophils per milligram of sputum and NO~2~ exposure level. In the global analysis, the slope of the association was significant (*p* = 0.02) ([Table 3](#t3){ref-type="table"}). The number of eosinophils per milligram of sputum increased by 120% (95% CI: 60, 202%) after 600 ppb NO~2~ (*p* \< 0.001) but not after clean air or after 200 ppb NO~2~ ([Table 3](#t3){ref-type="table"}).

Per-day analysis showed that the slope of the association between the percentage of eosinophils and NO~2~ exposure level was not significant at day 1 (*p* = 0.81), but was significant at day 2 (*p* = 0.01) and day 3 (*p* = 0.03). A similar pattern was found for the slope of the association between the number of eosinophils per milligram of sputum and the level of exposure to NO~2~, which was not significant at day 1 (*p* = 0.10), close to significance at day 2 (*p* = 0.06), and significant at day 3 (*p* = 0.03) ([Table 3](#t3){ref-type="table"}; see also Supplemental Material, Figure S1).

Compared with baseline measurements, there was no significant change of the percentage of eosinophils in sputum regardless of the level of exposure to NO~2~ at day 1. At day 2, the percentage and the number of eosinophils increased significantly at 600 ppb, but not at 200 ppb NO~2~. At day 3, the number of eosinophils increased significantly at 200 ppb and at 600 ppb NO~2~, and the increase of the percentage of eosinophils was close to significance at 600 ppb NO~2~, but not significant at 200 ppb ([Table 3](#t3){ref-type="table"}; see also Supplemental Material, Figure S1).

Absolute values not baseline adjusted \[GMs (95% CIs)\] of the percentages of eosinophils are reported in Supplemental Material, Table S2. Individual plots of the percentage of eosinophils are displayed in Supplemental Material, Figure S2. In order to see if results were driven by a participant in particular, we did a sensitivity analysis: a series of analyses with one different participant removed for each analysis. The trend test that measures the relationship between the dose of NO~2~ and the increase of the percentage of eosinophils in sputum from baseline was significant (*p* \< 0.05) in 10 of the tests, and was close to significance (*p* \< 0.10) for the other participants. Moreover, the increase of the percentage of eosinophils in sputum compared with baseline measurements was always significant at 600 ppb, regardless of which participant was removed from the analysis (see Supplemental Material, Table S3).

There was a significant correlation between the number of eosinophils per milligram of sputum and ECP (in nanograms per milliliter) (*p* \< 0.001) (see Supplemental Material, Figure S3).

Compared with baseline measurements, ECP in sputum increased significantly after exposure to 600 ppb NO~2~ (43%; 95% CI: 17, 75%; *p* = 0.001) but not after exposure to clean air or 200 ppb NO~2~. However, the slope of the association between ECP and the level of exposure was not significant ([Table 3](#t3){ref-type="table"}).

Exposure to NO~2~ did not affect the other cell types (macrophages, neutrophils) measured in sputum ([Table 3](#t3){ref-type="table"}).

There was no correlation between methacholine challenge tests and eosinophil responses (data not shown).

Discussion
==========

Our findings indicate that repeated brief exposures to NO~2~ without allergen exposure increase eosinophilic airway inflammation in participants with intermittent asthma without inducing any changes in lung function. Because only mild asthmatics were tested, the results cannot be extrapolated to healthy individuals.

Although we cannot exclude that repeated challenges with hypertonic saline could have potentialized the effect of NO~2~, the repetition of sputum inductions is not the cause of the effect because the effect is expected to be the same for each of the three series of exposures ([@r30]). Eosinophils in sputum increased according to NO~2~ exposure level, and this significant trend supports a dose-related relationship. The effect on eosinophils and on ECP in sputum was significant at 600 ppb NO~2~. We found a strong correlation between ECP and eosinophils, suggesting that eosinophils were activated.

In participants with asthma, several studies have found that NO~2~ exposure increased eosinophilic inflammation in response to inhaled allergen, in the distal lower airways assessed by bronchial wash and bronchoalveolar lavage (BAL) ([@r4]), and in sputum ([@r3]). The three previous studies that have investigated effects of NO~2~ without allergen challenge in participants with asthma did not find changes in inflammatory cell distributions in BAL ([@r24]) and in sputum ([@r36]; [@r42]). However, these studies involved small numbers of participants, and no repetition of exposure, and, in the study by [@r24], the evaluation of inflammation could have been performed too soon after exposure.

In the present study, participants with asthma were exposed to two realistic NO~2~ concentrations: 200 ppb and 600 ppb of NO~2~, which are close to NO~2~ peaks likely to be found indoors during the use of combustion appliances for cooking and heating ([@r5]; [@r9]; [@r26]; [@r31]) and outdoors for short periods in streets with heavy traffic and in road tunnels ([@r27]). Exposures lasted 30 min, close to the average time spent cooking dinner in France (38 min during the week and 46 min the weekend in a 2003 survey) ([@r17]). Furthermore, exposure to intermittent peaks of NO~2~ may have greater effects than long-term, low-level exposure ([@r11]).

Exposures in the present study were repeated over 2 days to mimic how exposures take place in real life and in order to assess a possible cumulative effect. At day 1, after one exposure, there was no significant change in eosinophilic airway inflammation---contrary to day 2 and day 3, after three exposures. These findings suggest that inflammatory response to NO~2~ exposure may be delayed or that a single exposure may be insufficient to enhance eosinophilic airway inflammation, suggesting a cumulative effect of NO~2~. These results are consistent with those of [@r3] who found that two to three brief exposures at 260 ppb NO~2~ were needed to promote an increase in the airway inflammatory response to inhaled allergens. In addition to the study by [@r3], our study shows that NO~2~, without an exposure to a high concentration of allergens, as with an allergen challenge, is sufficient to enhance inflammation in the airways. This finding could be of significance because exposure to peaks of NO~2~ is common, particularly indoors, whereas exposure to both high concentrations of NO~2~ and the specific stimulus for a susceptible individual is less likely ([@r18]).

Many cities in Europe show an increase in concentrations of NO~2~ measured close to traffic due to the increasing number of vehicles, in particular diesel vehicles. Exhaust emissions from diesel vehicles are lower for carbon monoxide, non-methanic volatile organic compounds, and particulate matter but may be higher for NO~2~ ([@r14]). Although epidemiological studies on NO~2~ have several limitations in particular because of the potential for exposure misclassification and co-pollutant effects, our results provide important evidence suggesting that NO~2~ alone has a direct effect on airway inflammation in asthmatics.

Conclusions
===========

To our knowledge, this is the first study to demonstrate that repeated peaks of NO~2~ at realistic concentrations without allergen exposure increase eosinophilic inflammation in the airways of asthmatics, supporting a dose--response relationship. Although it is difficult to evaluate the clinical implications of these findings in the present study, an increased eosinophilic inflammation may lead to exacerbation or loss of control of asthma ([@r13]; [@r19]). Therefore, we cannot rule out the effects of repeated exposures to NO~2~ over a longer period of time or effects in subpopulations.

Supplemental Material
=====================

###### 

Click here for additional data file.
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